Can You Take GLP-1 with Ozempic and Insulin Together?

Introduction

Yes. GLP-1 medications (semaglutide, tirzepatide, dulaglutide) are routinely combined with insulin in type 2 diabetes care. The combination often improves glucose control, reduces total insulin requirements, and supports weight loss compared to insulin alone. The SUSTAIN 5 trial (Rodbard et al. 2018 J Clin Endocrinol Metab) showed semaglutide added to basal insulin reduced A1c by an additional 1.4%.

The main caution: hypoglycemia risk. Insulin lowers blood sugar directly. GLP-1s improve insulin sensitivity and reduce hepatic glucose output. When started together or when GLP-1 is added to existing insulin therapy, insulin doses usually need to be reduced to prevent lows.

Typical practice when adding a GLP-1 to insulin therapy: reduce mealtime insulin by 20-25% and watch blood sugars closely for 1-2 weeks.

At TrimRx, we believe that understanding your options is the first step toward a more manageable health journey. You can take the free assessment quiz if you’re ready to see whether a personalized program is a fit for you.

Is GLP-1 Plus Insulin Safe?

Yes, when properly managed. The FDA has approved both semaglutide and tirzepatide for use with insulin in type 2 diabetes. Multiple large trials (SUSTAIN, AWARD, SURPASS programs) have studied this combination directly.

Quick Answer: GLP-1 and insulin combinations are standard practice in type 2 diabetes

Hypoglycemia is the main safety concern. In SUSTAIN 5, rates of severe hypoglycemia were low (about 1.6% on combo vs 1.4% on insulin alone), but mild hypoglycemia was more common. Patients with rapid A1c reductions and aggressive insulin dosing were at higher risk.

The combination doesn’t introduce new safety signals beyond what’s seen with each medication alone. The cardiovascular and renal benefits of GLP-1s persist when used with insulin.

How Much Should Insulin Be Reduced When Starting GLP-1?

Common practice: reduce mealtime (bolus) insulin by 20-25% on the first day of GLP-1 therapy, and reduce basal insulin by 10-15% if the patient has a history of fasting hypoglycemia or A1c below 8%.

For patients with A1c above 9%, the basal insulin may not need reduction initially since the glucose control is poor. As the GLP-1 takes effect over weeks, both basal and bolus doses usually need progressive reductions.

Continuous glucose monitoring (CGM) makes this transition far safer. Tracking time-in-range and identifying hypoglycemia patterns informs the dose adjustments. Many endocrinologists now require CGM for any patient combining insulin and GLP-1.

Does GLP-1 Plus Insulin Help with Weight?

Yes, substantially. Insulin alone tends to cause weight gain because it promotes fat storage and increases appetite. Adding a GLP-1 counteracts this effect.

In SUSTAIN 5, patients on the combination lost an average of 3.7 kg, while those on insulin alone gained 1.4 kg over the same period. The net difference of 5 kg matters clinically over years of therapy.

For patients with type 2 diabetes and obesity, combining a GLP-1 with insulin is often preferred over insulin alone because it addresses both glucose and weight together.

Can You Replace Insulin with GLP-1?

Sometimes. Many patients on basal insulin alone can transition off insulin when a GLP-1 is added, particularly those with type 2 diabetes whose insulin dose is moderate (under 60-80 units daily) and whose A1c has been close to target.

For patients on intensive insulin regimens (basal-bolus with high total daily doses), GLP-1 addition usually allows substantial dose reduction but rarely full discontinuation.

Type 1 diabetes is different. GLP-1 medications are not approved for type 1 diabetes, and insulin remains essential. Some clinicians use GLP-1 off-label in T1D for weight management, but never to replace insulin.

What About Tirzepatide and Insulin?

Same principles. The SURPASS-5 trial (Dahl et al. 2022 JAMA) studied tirzepatide added to titrated insulin glargine in type 2 diabetes. A1c reductions of 2.1-2.4% were achieved versus 0.9% with insulin alone, and patients lost 5.4-8.8 kg versus a 1.6 kg gain on insulin alone.

Insulin dose reductions averaged 20-50% during the trial. Hypoglycemia rates were similar to semaglutide-insulin combinations.

Tirzepatide’s dual GIP/GLP-1 mechanism produces slightly stronger glucose and weight effects than semaglutide, so insulin reductions may be larger when adding tirzepatide.

Key Takeaway: Insulin doses typically need to drop 20-25% when adding GLP-1 to prevent hypoglycemia

What Signs of Hypoglycemia Should You Watch For?

Classic symptoms: shakiness, sweating, dizziness, confusion, irritability, hunger, fast heartbeat. These typically appear when blood glucose drops below 70 mg/dL.

When starting a GLP-1 with insulin, check blood sugar more often, ideally with CGM or finger sticks before meals and at bedtime. Symptomatic hypoglycemia warrants immediate treatment with 15g of fast-acting glucose (3-4 glucose tabs, 4 oz juice).

Pattern recognition matters: repeated lows at the same time of day usually means a specific insulin dose needs reduction. Random lows can indicate dose-meal mismatch or activity changes.

Does GLP-1 Affect Insulin Absorption?

Minimally. GLP-1s slow gastric emptying, which can affect oral medication absorption, but insulin is injected subcutaneously and bypasses the GI tract. There’s no significant kinetic interaction.

The slowed gastric emptying does affect the timing of meal-related insulin needs. Food enters the small intestine more slowly, so postprandial glucose peaks are lower and later. Mealtime insulin may need to be timed differently, sometimes given after meals rather than before, particularly with rapid-acting insulin analogs.

This is a practical adjustment, not a safety problem.

How Do You Know When Insulin Is No Longer Needed?

Indicators that insulin may be discontinuable: A1c well below target (below 6.5%) for 3+ months, total daily insulin dose under 0.3 units per kg body weight, and frequent hypoglycemia despite reductions.

The decision to stop insulin should be made with your prescribing clinician, not unilaterally. Some patients can transition to GLP-1 alone or GLP-1 plus metformin. Others need to keep a low-dose basal insulin indefinitely.

TrimRx clinicians can coordinate with your endocrinologist on these transitions. A personalized treatment plan integrates GLP-1 therapy with existing diabetes management.

Bottom line: The combination reduces weight gain typical of insulin-only therapy

FAQ

Can You Take Ozempic® and Lantus Together?

Yes. This is a standard combination for type 2 diabetes. Insulin doses typically need adjustment when starting the GLP-1.

Will I Have Low Blood Sugar If I Add Semaglutide to Insulin?

The risk is increased, especially in the first 2-4 weeks. Monitor blood glucose frequently and reduce insulin doses preemptively.

Does Insulin Reduce GLP-1 Effectiveness?

No. The medications work through different mechanisms. They can be used together without losing the benefits of either.

Can Type 1 Diabetics Use GLP-1 with Insulin?

Off-label, sometimes for weight management. GLP-1 alone cannot replace insulin in type 1 diabetes.

Will My Insulin Needs Keep Dropping Over Time on GLP-1?

Often, yes. Weight loss improves insulin sensitivity, and continued A1c reduction can mean ongoing dose reductions. Re-evaluate monthly during the first 6 months.

Disclaimer: This content is for informational purposes only and does not constitute medical advice. It is not intended to diagnose, treat, cure, or prevent any disease or condition. Individual results may vary. Always consult a qualified healthcare professional before starting any weight loss program or medication.